Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exelixis, Inc. stock logo
EXEL
Exelixis
$40.37
-0.9%
$40.30
$21.82
$48.85
$11.11B0.282.39 million shs6.76 million shs
Qiagen N.V. stock logo
QGEN
Qiagen
$46.72
+0.4%
$43.59
$37.63
$49.30
$10.35B0.671.19 million shs2.12 million shs
Repligen Corporation stock logo
RGEN
Repligen
$118.85
+1.1%
$128.71
$102.97
$182.52
$6.60B1.1734,224 shs770,906 shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$49.89
-0.5%
$49.51
$46.01
$83.62
$7.86B1.381.43 million shs2.58 million shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%-2.49%-8.16%+10.23%+88.96%
Qiagen N.V. stock logo
QGEN
Qiagen
0.00%-1.77%+8.94%+17.22%+9.42%
Repligen Corporation stock logo
RGEN
Repligen
0.00%-10.48%-7.88%-16.05%-4.44%
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.00%-2.72%+1.21%-17.29%-32.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Exelixis, Inc. stock logo
EXEL
Exelixis
4.4863 of 5 stars
2.22.00.04.32.32.53.8
Qiagen N.V. stock logo
QGEN
Qiagen
2.9295 of 5 stars
1.12.00.84.51.91.71.3
Repligen Corporation stock logo
RGEN
Repligen
4.6477 of 5 stars
4.31.00.04.52.91.71.9
Bio-Techne Corp stock logo
TECH
Bio-Techne
4.8683 of 5 stars
4.23.01.74.22.91.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Exelixis, Inc. stock logo
EXEL
Exelixis
2.47
Hold$39.76-1.50% Downside
Qiagen N.V. stock logo
QGEN
Qiagen
2.22
Hold$47.742.18% Upside
Repligen Corporation stock logo
RGEN
Repligen
2.69
Moderate Buy$173.2545.77% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.45
Hold$72.0044.32% Upside

Current Analyst Ratings Breakdown

Latest QGEN, TECH, RGEN, and EXEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/12/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $47.00
6/5/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$45.00 ➝ $46.00
6/5/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
5/30/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$59.00
5/15/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$45.00
5/15/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $56.00
5/14/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$40.00 ➝ $47.00
5/14/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/14/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00
5/14/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$36.00 ➝ $38.00
5/9/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$95.00 ➝ $70.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.17B5.08$1.91 per share21.15$7.86 per share5.14
Qiagen N.V. stock logo
QGEN
Qiagen
$1.98B5.25$3.22 per share14.52$16.05 per share2.91
Repligen Corporation stock logo
RGEN
Repligen
$634.44M10.52$3.14 per share37.83$35.21 per share3.38
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.16B6.75$2.30 per share21.66$13.13 per share3.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Exelixis, Inc. stock logo
EXEL
Exelixis
$521.27M$2.2018.3515.830.8327.99%28.81%21.94%8/5/2025 (Estimated)
Qiagen N.V. stock logo
QGEN
Qiagen
$83.59M$0.40117.1418.992.374.68%14.61%8.80%7/30/2025 (Estimated)
Repligen Corporation stock logo
RGEN
Repligen
-$25.51M-$0.45N/A50.363.37-3.93%4.53%3.17%7/29/2025 (Estimated)
Bio-Techne Corp stock logo
TECH
Bio-Techne
$168.10M$0.8260.8425.322.6510.89%13.17%10.17%8/6/2025 (Estimated)

Latest QGEN, TECH, RGEN, and EXEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Qiagen N.V. stock logo
QGEN
Qiagen
$0.50$0.55+$0.05$0.41$465.66 million$483.46 million
5/7/2025Q3 2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.51$0.56+$0.05$0.14$317.92 million$316.18 million
4/29/2025Q1 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.35$0.39+$0.04$0.10$163.65 million$169.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Qiagen N.V. stock logo
QGEN
Qiagen
N/AN/AN/AN/AN/A
Repligen Corporation stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.64%N/A39.02%N/A

Latest QGEN, TECH, RGEN, and EXEL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/19/2025
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.67%5/19/20255/19/20255/30/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.50
3.44
Qiagen N.V. stock logo
QGEN
Qiagen
0.40
3.37
2.83
Repligen Corporation stock logo
RGEN
Repligen
0.27
6.79
5.79
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.16
3.71
2.58

Institutional Ownership

CompanyInstitutional Ownership
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Qiagen N.V. stock logo
QGEN
Qiagen
70.00%
Repligen Corporation stock logo
RGEN
Repligen
97.64%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Exelixis, Inc. stock logo
EXEL
Exelixis
2.82%
Qiagen N.V. stock logo
QGEN
Qiagen
9.00%
Repligen Corporation stock logo
RGEN
Repligen
1.20%
Bio-Techne Corp stock logo
TECH
Bio-Techne
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,147272.71 million265.02 millionOptionable
Qiagen N.V. stock logo
QGEN
Qiagen
5,765222.29 million202.29 millionOptionable
Repligen Corporation stock logo
RGEN
Repligen
1,77856.18 million55.51 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.77 million150.65 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Exelixis stock logo

Exelixis NASDAQ:EXEL

$40.37 -0.37 (-0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$40.48 +0.11 (+0.26%)
As of 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Qiagen stock logo

Qiagen NYSE:QGEN

$46.72 +0.17 (+0.36%)
Closing price 03:59 PM Eastern
Extended Trading
$46.76 +0.04 (+0.09%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Repligen stock logo

Repligen NASDAQ:RGEN

$118.85 +1.31 (+1.11%)
Closing price 04:00 PM Eastern
Extended Trading
$118.84 0.00 (0.00%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$49.89 -0.24 (-0.48%)
Closing price 04:00 PM Eastern
Extended Trading
$50.14 +0.25 (+0.50%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.